Week of May 2, 2022 | Vol. 11, Issue 18
Events Hosted or Attended by Bourne Partners
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
June 13-16, 2022 - San Diego, CA
June 19-23, 2022 - Chicago IL
August 27-29, 2022 - Boston, MA
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
Insight Into Healthcare Related Industries
Representative Current Retained Sell-Side And Partnering Opportunities
Project Gateway
Sell-side | Pharma | Generic pharmaceuticals

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company

Project Panther
[Buy/sell]-side| [Pharma, CDMO, Generic Pharma, etc.] | [What the company does]
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
A Sampling of Industry Headlines From Last Week
Days after throwing down $350 million to beef up biologics manufacturing in Indiana, high-flying CDMO Catalent is buying a cell therapy plant on the East Coast.
Three years ago, technology startup Biofourmis had raised $10 million in total funding. This week, the virtual care and digital medicine-focused company announced a massive $300 million cash injection to fuel its growth.
Pfizer is throwing its weight behind Zentalis Pharmaceuticals’ synthetic lethality candidate, making a $25 million investment in its new partner and agreeing to jointly advance the prospect through the clinic.
Oticon Medical’s ears must be burning after parent company Demant struck a deal to divest the implant business in a sale to fellow hearing technology developer Cochlear.

Tanner was honored to serve as the presenting sponsor of The Max Foundation's annual Max Gala, and to help amplify the voices of cancer patients around the world. Through the support of many, the gala raised more than $260,000 in support of Max's mission to accelerate health equity. Learn more about Tanner's partnership with Max and the impacts of the Max Access Solutions program.

Tanner Pharma announced last week its expansion to Ireland with the opening of a new office space in Cork, the country’s third largest city. The new location was selected after many months of travel and research by Tanner’s executive team.

The Tanner team will be attending several networking events in the coming weeks. Let’s connect to discuss how our organizations can improve patient lives, together.